Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 19/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 19/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469153 | 0.80 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL29677229 | 0.80 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL24469167 | 0.75 | P2RX3 (0.41) | P2RX3P2RX2 | |
| SCHEMBL24469147 | 0.75 | P2RX3 (0.39) | P2RX3P2RX2 | |
| SCHEMBL24674487 | 0.71 | LMNA (0.40) | P2RX3P2RX2 | |
| SCHEMBL22714752 | 0.69 | PDE5A (0.36) | P2RX3P2RX2 | |
| SCHEMBL24469170 | 0.66 | P2RX3 (0.37) | P2RX3P2RX2 | |
| SCHEMBL29564487 | 0.65 | MAP4K4 (0.36) | — | |
| SCHEMBL24469159 | 0.63 | MCHR1 (0.33) | — | |
| SCHEMBL22715145 | 0.63 | LMNA (0.38) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | claimed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | claimed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | claimed |
| EP-4251273-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | claimed |
| CN-116745284-A | Phthalazine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | claimed |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | disclosed |
| EP-4251273-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| CN-116745284-A | Phthalazine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | P2RX3 1/4885P2RX2 6/4885PLK4 3731/4885 |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885P2RX2 3/4885PLK4 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.